@article{oai:nagasaki-u.repo.nii.ac.jp:00014758,
 author = {Nakamura, Yoichi and Soda, Hiroshi and Oka, Mikio and Kinoshita, Akitoshi and Fukuda, Minoru and Fukuda, Masaaki and Takatani, Hiroshi and Nagashima, Seiji and Soejima, Yoshifumi and Kasai, Takashi and Nakatomi, Katsumi and Masuda, Noriyuki and Tsukamoto, Kazuhiro and Kohno, Shigeru},
 issue = {1},
 journal = {Journal of Thoracic Oncology : official publication of the International Association for the Study of Lung Cancer},
 month = {Jan},
 note = {Irinotecan-containing regimens are known to be active and tolerable in patients with non-small cell lung cancer (NSCLC). A randomized phase II trial was conducted to evaluate the efficacy of irinotecan plus paclitaxel or gemcitabine for previously untreated stage IIIB or stage IV NSCLC., Journal of Thoracic Oncology, 6(1), pp.121-127; 2011},
 pages = {121--127},
 title = {Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.},
 volume = {6},
 year = {2011}
}